Lexeo Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LXEO | RCKT | TNYA | SLDB | RGNX | DSGN | |
|---|---|---|---|---|---|---|
| Market cap | 265.14M | 286.51M | 84.31M | 699.11M | 508.96M | 665.24M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.4 | -1.6 | -0.9 | -3.8 | -2.6 | -6.6 |
| Price/book | 1.1 | 0.8 | 1.2 | 2.9 | 5.8 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −62.07% | −19.20% | −73.91% | +54.69% | −30.98% | +57.86% |
| Today | +3.86% | +3.98% | +2.66% | +3.82% | +1.05% | +2.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LXEO news ›Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
Posted by Kim Johansen on Oct 25th, 2026 CEO Nolan Townsend said PKP2 ACM is a serious, progressive genetic heart disease with no approved therapies designed to modify its course. The company estimates that about 60,000 people in the…
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow
2026-10-24. The following slide deck was published by Lexeo Therapeutics, Inc. The following slide deck was published by Lexeo Therapeutics, Inc. in conjunction with this event.
JPMORGAN CHASE & CO Acquires 4,573,701 Shares of Lexeo Therapeutics Inc (LXEO)
GuruFocus JPMORGAN CHASE & CO Acquires 4,573,701 Shares of Lexeo Therapeutics Inc (LXEO) A Significant Position Increase in Clinical-Stage Genetic Medicine On September 30, 2026, JPMORGAN CHASE & CO executed a substanti
AutoZone grants Lucas J. Rauch 3,500 stock options
The options carry a $2,939.85 exercise price per share and expire October 9, 2036. Rauch received the award October 9, 2026, as merchandising and sourcing SVP. AutoZone grants Lucas J. Rauch 3,500 stock options The award has a…
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need,... NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- gurufocus.com1
- manilatimes.net1
- nasdaq.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.